<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863001</url>
  </required_header>
  <id_info>
    <org_study_id>antiarrhythmic drugs in pediat</org_study_id>
    <nct_id>NCT04863001</nct_id>
  </id_info>
  <brief_title>Use of Antiarrhythmic Drugs in Pediatrics</brief_title>
  <official_title>Adescriptive Study on the Use of Antiarrhythmic Drugs in Pediatrics Cardiology Unit Assiut University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe the use of Cardiovascular Drugs in Pediatrics Cardiology unit&#xD;
      Assiut University. As regard :&#xD;
&#xD;
        -  indications of use .&#xD;
&#xD;
        -  proper dosage.&#xD;
&#xD;
        -  proper management of side effects of their use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arrhythmias occur in children and adolescents with congenital heart disease as well as those&#xD;
      with structurally normal hearts. Antiarrhythmic medications primarily affect the ion channels&#xD;
      in cardiac myocytes that are responsible for generating currents that create the action&#xD;
      potential.&#xD;
&#xD;
      By altering the activity of these ion channels, the action potential is changed in an attempt&#xD;
      to reduce the likelihood of sustained arrhythmias. There is awide range of antiarrhysmic&#xD;
      drugs used in treatment Antiarrhysmics are therefore divided into five classes&#xD;
&#xD;
      Class I: Antiarrhythmics that affect sodium channels (slow depolarization) Class II: Drugs&#xD;
      that counteract the sympathetic nervous system, predominantly beta-blockers Class III: drugs&#xD;
      that affect the potasium channels ( prolong repolarization) Class IV: Drugs that affect&#xD;
      calcium channels (Calcium channel blockers) Class V: Vagotonic drugs (Digoxin) and other&#xD;
      miscellaneous drugs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>descripe the use of antiarrhythmic drugs in pediatrics</measure>
    <time_frame>one year</time_frame>
    <description>to asses the use of antiarrhythmic drugs in cardiology unit whether its used for proper indications matching with last guidelines or not to asses also dosage (gram per Kg of weight) of each drug used .and detrimine the side effects appear and its proper management.&#xD;
proper dosage.&#xD;
proper management of side effects of their use</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antiarrhythmic Toxicity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug</intervention_name>
    <description>all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1- Patients' selection:- patients from 1 month age till 18 years on antiarrhythmic&#xD;
        medications in Cardiology Unit Assiut University Hospital antiarrhytmic medications .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Patients with Arrhythmic cardiac diseases admitted at cardiology unit Assiut&#xD;
             University Hospital aged from 1 month to 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ‚óè Patients with diseases rather than arrhythmic cardiac diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Areej makhlouf</last_name>
    <phone>01001153846</phone>
    <email>areejmakhlouf2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salah Eldin Ahmad</last_name>
    <email>S_amry@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Podrid PJ. Antiarrhythmic drug selection. Annu Rev Med. 1987;38:1-17. Review.</citation>
    <PMID>3555284</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Areej Tarek Mostafa mohamed makhlouf</investigator_full_name>
    <investigator_title>Principle investegator , Areej Tarek Mostafa</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

